The BPIA 2026 Annual Meeting held in Washington, DC on March 4-6 included three tracks covering a variety of regulatory, technical, and commercial topics with speakers from EPA, USDA, CFIA, PMRA, and AAPFCO.
As we reflect on 2025, BPIA would like to thank all our partners for their continued engagement and help in promoting the biological products industry.
BPIA applauds last week’s announcement from the USDA in collaboration with HHS launching a $700 million Regenerative Pilot Program.
The BPIA 2026 Annual Meeting held in Washington, DC on March 4-6 included three tracks covering a variety of regulatory, technical, and commercial topics with speakers from EPA, USDA, CFIA, PMRA, and AAPFCO.
As we reflect on 2025, BPIA would like to thank all our partners for their continued engagement and help in promoting the biological products industry.
As the year draws to a close, we want to extend our heartfelt thanks to our members and colleagues for your engagement, leadership, and commitment to the biological products industry.
BPIA applauds last week’s announcement from the USDA in collaboration with HHS launching a $700 million Regenerative Pilot Program.
Please join us at the historic Capital Hilton in Washington, D.C., on March 4-6, 2026, for the BPIA 2026 Annual Meeting. Don’t miss the most important annual gathering for the biological products industry in North America.
BPIA congratulates Dudley Hoskins on his confirmation as Under Secretary for the U.S. Department of Agriculture’s Marketing and Regulatory Programs.
BPIA joined a coalition of industry associations in sending a letter to Congressional leadership urging swift, bipartisan passage of the Fiscal Year 2026 Interior, Environment, and Related Agencies appropriations bill.
BPIA has submitted comments to the National Organic Standards Board in advance of its Fall 2025 Meeting.
BPIA submitted comments in response to the U.S. Department of Justice’s Request for Information on State Laws Having Significant Adverse Effects on the National Economy or Significant Adverse Effects on Interstate Commerce.
BPIA released a statement today in response to the White House’s Make Our Children Healthy Again strategy, emphasizing the role that biological products can play in supporting public health.
BPIA urges USDA to maintain its presence in Washington, D.C., protect research hubs that are vital for biological products, and ensure that regional offices align with centers of agricultural demand.
BPIA’s Inert Ingredients in Biological Products Symposium will be on December 4, 2025, at the North Carolina Biotechnology Center. This event is sold out!
BPIA applauds the Food and Agriculture Climate Alliance for recognizing the importance of biostimulants in its forward-looking report, Nurturing Healthy Soils for Healthy Communities.
BPIA submitted a letter to Congress encouraging lawmakers to cosponsor the Plant Biostimulant Act of 2025, H.R. 3783 / S. 1907 (PBA).
BPIA has submitted a letter to USDA-NIFA in support of the IR-4 Project and its important role in advancing the development and regulatory approval of biological crop protection tools.
BPIA and other stakeholders sent a letter to House appropriators responding to the President’s FY2026 Budget in Brief and asking for support of EPA’s Office of Pesticide Programs including the Biopesticides and Pollution Prevention Division.
BPIA proudly supports the reintroduction of the bipartisan Plant Biostimulant Act (PBA) in the U.S. Senate by Senators Alex Padilla (D-CA) and Roger Marshall (R-KS).
BPIA submitted comments in response to the Department of Justice Antitrust Division’s request for public input on anticompetitive regulations.
BPIA proudly supports the reintroduction of the bipartisan Plant Biostimulant Act in the U.S. House of Representatives.
BPIA welcomes the release of the “Making Our Children Healthy Again” assessment from the Make America Healthy Again Commission.